Uri Kopylov1, Irit Avni-Biron2, Yulia Ron3, Benjamin Koslowsky4, Matti Waterman5, Saleh Daher6, Bella Ungar1, Doron Schwartz7, Eran Zittan8, Michal Openhaim9, Henit Yanai2, Nitsan Maharshak3, Ariella Bar Gil Shitrit4, Timna Naftali9, Rami Eliakim1, Yehuda Chowers5, Shomron Ben-Horin1, Iris Dotan10. 1. Department of Gastroenterology, Sheba Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 2. Division of Gastroenterology, Rabin Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 4. Digestive Diseases Institute, Shaare Zedek Medical Center, Affiliated with the Faculty of Medicine, Hebrew University, Jerusalem, Israel. 5. Department of Gastroenterology, Rambam Healthcare Campus, Affiliated with the Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. 6. Department of Gastroenterology, Hadassah Medical Center, Affiliated with the Faculty of Medicine, Hebrew University, Jerusalem, Israel. 7. Department of Gastroenterology, Soroka Medical Center, Affiliated with the Faculty of Medicine, Ben Gurion University, Beer Sheva, Israel. 8. Department of Gastroenterology, Haemek Medical Center, Affiliated with the Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. 9. Department of Gastroenterology, Meir Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 10. Division of Gastroenterology, Rabin Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: ukopylov@gmail.com.
Abstract
INTRODUCTION: Several real-world experience (RWE) studies with vedolizumab (VDZ) for induction of remission in inflammatory bowel diseases (IBD) have been published; however, long-term RWE data is scarce. AIMS: To describe the effectiveness and safety of VDZ in maintenance treatment of IBD. METHODS: A multicenter retrospective national study. The primary outcome of was clinical response at week 52; main secondary aims included clinical remission at week 52, rates of secondary loss of response and treatment discontinuation. RESULTS: We included 193 (133-CD; 60-UC) patients from 9 Israeli IBD centers. At week 52, response was observed in 62/133 (46.7%) CD patients, including 28 (21%) in clinical remission; 71 (53.3%) discontinued treatment or did not respond. For UC, response at week 52 was observed in 27/60 (45%), including 20 (33%) in clinical remission; 33 (55%) discontinued treatment or did not respond. Secondary non-response by week 52 occurred in 19.4% and 23.5% of week 14 responders in CD and UC, respectively. Week 14 response was associated with treatment continuation at week 52: no predictors of secondary loss of response were identified. SUMMARY: VDZ is safe and effective for maintenance of response and remission in IBD; week 14 response is positively associated with long-term response in both UC and CD.
INTRODUCTION: Several real-world experience (RWE) studies with vedolizumab (VDZ) for induction of remission in inflammatory bowel diseases (IBD) have been published; however, long-term RWE data is scarce. AIMS: To describe the effectiveness and safety of VDZ in maintenance treatment of IBD. METHODS: A multicenter retrospective national study. The primary outcome of was clinical response at week 52; main secondary aims included clinical remission at week 52, rates of secondary loss of response and treatment discontinuation. RESULTS: We included 193 (133-CD; 60-UC) patients from 9 Israeli IBD centers. At week 52, response was observed in 62/133 (46.7%) CDpatients, including 28 (21%) in clinical remission; 71 (53.3%) discontinued treatment or did not respond. For UC, response at week 52 was observed in 27/60 (45%), including 20 (33%) in clinical remission; 33 (55%) discontinued treatment or did not respond. Secondary non-response by week 52 occurred in 19.4% and 23.5% of week 14 responders in CD and UC, respectively. Week 14 response was associated with treatment continuation at week 52: no predictors of secondary loss of response were identified. SUMMARY: VDZ is safe and effective for maintenance of response and remission in IBD; week 14 response is positively associated with long-term response in both UC and CD.
Authors: Liege I Diaz; Tara Keihanian; Ingrid Schwartz; Su Bin Kim; Fernando Calmet; Maria Alejandra Quintero; Maria T Abreu Journal: Gastroenterol Hepatol (N Y) Date: 2020-02
Authors: Carl Eriksson; Sara Rundquist; Vyron Lykiardopoulos; Ruzan Udumyan; Per Karlén; Olof Grip; Charlotte Söderman; Sven Almer; Erik Hertervig; Jan Marsal; Jenny Gunnarsson; Carolina Malmgren; Jenny Delin; Hans Strid; Mats Sjöberg; David Öberg; Daniel Bergemalm; Henrik Hjortswang; Jonas Halfvarson Journal: Therap Adv Gastroenterol Date: 2021-07-03 Impact factor: 4.409